个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Zhou, Qing[1,2] * ; Xu, Chong-Rui[1,2] ; Cheng, Ying[3] ; Liu, Yun-Peng[4] ; Chen, Gong-Yan[5] ; Cui, Jiu-Wei[6] ; Yang, Nong[7] ; Song, Yong[8] ; Li, Xiao-Ling[9] ; Lu, Shun[10] ; Zhou, Jian-Ying[11] ; Ma, Zhi-Yong[12] ; Yu, Shi-Ying[13] ; Huang, Cheng[14] ; Shu, Yong-Qian[15] ; Wang, Zhen[1,2] ; Yang, Jin-Ji[1,2] ; Tu, Hai-Yan[1,2] ; Zhong, Wen-Zhao[1,2] ; Wu, Yi-Long[1,2] ;
单位： [1]Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China [2]Guangdong Acad Med Sci, Guangzhou, Peoples R China [3]Jilin Prov Tumor Hosp, Dept Thorac Oncol, Changchun, Peoples R China [4]First Hosp China Med Univ, Dept Med Oncol, Shenyang, Peoples R China [5]Canc Hosp Harbin Med Univ, Med Oncol, Harbin, Peoples R China [6]First Hosp Jilin Univ, Canc Ctr, Changchun, Peoples R China [7]Hunan Canc Hosp, Dept Med Oncol, Changsha, Peoples R China [8]Nanjing Univ Sch Med, Jinling Hosp, Dept Resp Med, Nanjing, Peoples R China [9]Liaoning Canc Hosp, Med Oncol, Shenyang, Peoples R China [10]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Med Oncol, Shanghai, Peoples R China [11]Zhejiang Univ, Affiliated Hosp 1, Resp Med, Coll Med, Hangzhou, Peoples R China [12]Zhengzhou Univ, Dept Resp Med, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China [13]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Med Oncol, Wuhan, Peoples R China [14]Fujian Canc Hosp, Med Oncol, Fuzhou, Peoples R China [15]Nanjing Med Univ, Affiliated Hosp 1, Med Oncol, Nanjing, Peoples R China
出处：
DOI： 10.1016/j.ccell.2021.07.005
ISSN：

摘要：
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung cancer (NSCLC). This phase 3 study investigated the efficacy and safety of an erlotinib plus bevacizumab regimen in untreated patients with advanced NSCLC. In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinib only (n = 154). Progression-free survival (PFS) was 17.9 months (95% confidence interval [CI], 15.2-19.9) for bevacizumab plus erlotinib and 11.2 months (95% CI, 9.7-13.8) for erlotinib only (hazard ratio [HR] = 0.55; 95% CI, 0.41-0.73; p < 0.001). A brain metastases subgroup treated with bevacizumab plus erlotinib also showed improved PFS (HR = 0.48; 95% CI, 0.27-0.84; p = 0.008). Grade >= 3 treatment-related adverse events occurred in 86 (54.8%) and 40 (26.1%) patients, respectively. Bevacizumab plus erlotinib significantly improved PFS in patients with untreated metastatic EGFR-mutated NSCLC, including those with brain metastases at baseline.

基金：
National Key R&D Program of China [2016YFC1303800]; Chinese Thoracic Oncology Group (CTONG); High-level Hospital Construction Project [DFJH201810]; CTONG
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 1 区 医学
小类 | 1 区 细胞生物学 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 细胞生物学 1 区 肿瘤学
JCR分区：
出版当年[2019]版：
Q1 CELL BIOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 CELL BIOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者单位： [1]Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China [2]Guangdong Acad Med Sci, Guangzhou, Peoples R China
通讯作者：
通讯机构： [1]Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Peoples R China [2]Guangdong Acad Med Sci, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou Qing,Xu Chong-Rui,Cheng Ying,et al.Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study[J].CANCER CELL.2021,39(9):1279-+.doi:10.1016/j.ccell.2021.07.005.
APA：
Zhou, Qing,Xu, Chong-Rui,Cheng, Ying,Liu, Yun-Peng,Chen, Gong-Yan...&Wu, Yi-Long.(2021).Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.CANCER CELL,39,(9)
MLA：
Zhou, Qing,et al."Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study".CANCER CELL 39..9(2021):1279-+

资源点击量：428 今日访问量：2 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）